Evidence map›Paper›PMID 39591158›Full record

ArticleVaccines2024

Safety and Immunogenicity of Intranasal Razi Cov Pars as a COVID-19 Booster Vaccine in Adults: Promising Results from a Groundbreaking Clinical Trial.

Mohammad Hossein Fallah Mehrabadi, Monireh Hajimoradi, Ali Es-Haghi, Saeed Kalantari, Mojtaba Noofeli, Ali Rezaei Mokarram, Seyed Hossein Razzaz, Maryam Taghdiri, Ladan Mokhberalsafa, Fariba Sadeghi and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Molecular mechanisms of SARS-CoV-2 entry: implications for biomedical strategies.Microbiology and molecular biology reviews : MMBR · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Mohammad Hossein Fallah MehrabadiDepartment of Epidemiology, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), P.O. Box 31975/148, Karaj, Iran.
Monireh HajimoradiDepartment of Immunology, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), P.O. Box 31975/148, Karaj, Iran.ORCID 0000-0002-0197-3993
Ali Es-HaghiDepartment of Physico Chemistry, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), P.O. Box 31975/148, Karaj, Iran.ORCID 0000-0001-6533-3656
Saeed KalantariDepartments of Infectious Diseases and Tropical Medicine, Iran University of Medical Sciences, P.O. Box 354-14665, Tehran, Iran.
Mojtaba NoofeliDepartment of Recombinant Antigens Research, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), P.O. Box 31975/148, Karaj, Iran.
Ali Rezaei MokarramDepartment of Adjuvant and formulation Research, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), P.O. Box 31975/148, Karaj, Iran.ORCID 0000-0003-3777-4854
Seyed Hossein RazzazDepartment of Immunology, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), P.O. Box 31975/148, Karaj, Iran.
Maryam TaghdiriDepartment of Immunology, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), P.O. Box 31975/148, Karaj, Iran.ORCID 0000-0002-6825-9006
Ladan MokhberalsafaClinical Trial and Ethics Group, Department of QA, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), P.O. Box 31975/148, Karaj, Iran.ORCID 0000-0002-9437-4067
Fariba SadeghiDepartment of QC, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), P.O. Box 31975/148, Karaj, Iran.
Vahideh MohseniSchool of Public Health, Iran University of Medical Sciences, P.O. Box 354-14665, Tehran, Iran.
Safdar MasoumiDepartment of Biostatistics, Tarbiat Modares University, P.O. Box 14115-111, Tehran, Iran.
Rezvan Golmoradi-ZadehDepartment of Microbiology, School of Medicine, Iran University of Medical Sciences, P.O. Box 354-14665, Tehran, Iran.
Mohammad Hasan RabieeDepartment of Epidemiology, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), P.O. Box 31975/148, Karaj, Iran.ORCID 0000-0002-8355-1478
Masoud Solaymani-DodaranDepartment of Epidemiology, Iran University of Medical Sciences, P.O. Box 354-14665, Tehran, Iran.
Seyed Reza BanihashemiDepartment of Immunology, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), P.O. Box 31975/148, Karaj, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protective antibodies in the upper respiratory tract prevent the spread of COVID-19 in the community. Intranasal vaccines could raise the specific secretory IgA and IgG levels. This is a single-center, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and immunogenicity of Razi Cov Pars (RCP) intranasal recombinant protein subunit COVID-19 vaccine as a booster in adults. We compared specific IgG and IgA levels in the intranasal RCP group (

Indexed as

boosterclinical trialCOVID-19intranasal recombinant protein subunit vaccinemucosal immunityRazi Cov Pars

Identifiers

PMID39591158
PMCPMC11598910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.